Close

Altimmune (ALT) Announces Lean Mass Preservation Data for Pemvidutide Mar 27, 2024 07:07AM
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results Mar 27, 2024 07:00AM
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 Mar 20, 2024 07:30AM
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT Feb 24, 2024 01:15PM
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT Feb 19, 2024 04:53PM
View Older Stories

Jan 2, 2024 07:30AM Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
Nov 30, 2023 04:27PM Altimmune (ALT) Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Nov 30, 2023 04:24PM Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
Nov 7, 2023 07:00AM Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
Oct 31, 2023 07:30AM Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
Oct 26, 2023 07:31AM Altimmune (ALT) Granted FDA Fast Track Designation for Pemvidutide
Oct 26, 2023 07:30AM Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Oct 25, 2023 07:30AM Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
Oct 17, 2023 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
Sep 26, 2023 07:30AM Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
Sep 12, 2023 07:30AM Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Aug 30, 2023 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
Aug 10, 2023 07:00AM Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
Aug 3, 2023 07:30AM Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Aug 1, 2023 07:30AM Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Jun 16, 2023 07:30AM Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
Jun 15, 2023 07:30AM Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023
May 31, 2023 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
May 11, 2023 07:00AM Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
May 8, 2023 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
May 4, 2023 07:30AM Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Apr 11, 2023 07:30AM Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
Mar 27, 2023 04:05PM Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
Mar 21, 2023 07:00AM Altimmune (ALT) Reports Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial
Mar 21, 2023 07:00AM Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial
Feb 28, 2023 07:00AM Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
Feb 21, 2023 07:30AM Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
Jan 4, 2023 07:30AM Altimmune Appoints Raymond Jordt as Chief Business Officer
Jan 4, 2023 07:30AM Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
Dec 20, 2022 07:02AM Altimmune (ALT) Reports Positive Topline Results from 24-Week Trial of Pemvidutide
Dec 20, 2022 07:00AM Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
Nov 22, 2022 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
Nov 10, 2022 07:00AM Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
Nov 3, 2022 07:30AM Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
Oct 28, 2022 07:30AM Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
Sep 28, 2022 07:30AM Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Sep 14, 2022 07:00AM Altimmune (ALT) Reports Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide
Sep 14, 2022 07:00AM Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
Aug 11, 2022 07:00AM Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
Aug 4, 2022 07:30AM Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11
Jun 17, 2022 07:30AM Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on June 25, 2022
Jun 3, 2022 07:30AM Altimmune to Participate at Two Upcoming Investor Conferences
May 31, 2022 07:30AM Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
May 20, 2022 07:30AM Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
May 16, 2022 07:30AM Altimmune to Present at Upcoming Investor Conferences
May 12, 2022 07:00AM Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
May 5, 2022 07:30AM Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12
Apr 1, 2022 07:02AM Altimmune (ALT) Initiates Phase 2 Trial of Pemvidutide in Obesity
Apr 1, 2022 07:00AM Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
Mar 15, 2022 07:01AM Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
View Older Stories